Recurrent Respiratory Papillomatosis (RRP)—Juvenile Onset by Dyrstad, Sara W. & Rao, Krishna A.
Clinical Medicine: Oncology 2008:2 481–486 481
CASE REPORT
Correspondence: Krishna A. Rao, M.D., Ph.D., Assistant Professor of Medicine, Division of Hematology/
Oncology, Department of Internal Medicine, Southern Illinois University School of Medicine, Post Ofﬁ  ce Box 
19678, Springﬁ  eld, IL 62794-9678. Tel: 217-545-5817, Fax: 217-545-7021, Email: krao@siumed.edu
Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the 
Creative Commons Attribution By licence. For further information go to: http://creativecommons.org/licenses/by/3.0/.
Recurrent Respiratory Papillomatosis (RRP)—Juvenile 
Onset
Sara W. Dyrstad and Krishna A. Rao
Department of Internal Medicine, Southern Illinois University School of Medicine, 415 North Ninth 
Street, Post Office Box 19678, Springfield, IL 62794-9678 U.S.A.
Abstract: In this article, we describe the treatment of long standing juvenile-onset recurrent respiratory papillomatosis 
(JORRP) with eventual transformation to carcinoma in a patient who lived to the age of 73. Treatment modalities consisted 
of bronchoscopy and local excision initially. Later, YAG and CO2 laser debulking were used. Radiotherapy, chemotherapy 
with carboplatin (300 mg/m2) and 5-FU (600 mg/m2), oral methotrexate (5–7.5 mg/week), pegylated Interferon, 
indole-3-carbamide, and intralesional cidofovir were also utilized in the treatment of this patient. Except for methotrexate, 
each of the treatment regimens used in this patient, initially decreased growth of the papillomas and improved symptoms 
experienced by the patient. Interestingly, we found that this patient’s long standing JORRP initially responded to a chemo-
therapy regimen of 4 cycles of carboplatin (300 mg/m2) and 5-FU (600 mg/m2) as well. Ultimately, the disease became 
resistant to all forms of treatment and progressed. The patient eventually succumbed to the disease after an approximate 
77 year course.
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Background
Recurrent Respiratory Papillomatosis (RRP) is caused by certain strains of the human papilloma virus, 
HPV-6 and HPV-11.(Auborn, 2002) This highly morbid disease can begin in childhood or adulthood. 
However, only 4 to 6 per 100,000 people exposed to HPV-6 or HPV-11 develop this disease. In children, 
this disease normally presents before the age of 5 and is referred to as juvenile onset RRP (JORRP). 
JORRP is usually thought to be vertically transmitted to the child during childbirth, although placental 
transmission has also been reported (Wang, 1998).
In adults, this disease commonly presents in the fourth decade of life and is referred to as adult onset 
RRP (AORRP). The cause of AORRP is unknown. But, sexual transmission is suspected. Males have 
a higher risk (4-fold) when compared to females in developing AORRP.(Auborn, 2002) RRP usually 
develops at the junction between squamous and columnar epithelial cells, such as the vocal cords, 
subglottis, laryngeal side of epiglottis, and trachea. Altered immune response to HPV proteins has been 
hypothesized as a factor involved in the development of RRP.(DeVoti et al. 2004) Because pregnancy 
has been found to enhance disease progression, hormonal factors are thought to be involved in the 
pathogenesis of RRP. The morbidities associated with any form of RRP are due to bronchial obstruction 
and the use of procedures and multiple drug regimens necessary to deter the growth of the 
papillomas.(Auborn, 2002)
Treatment for RRP normally consists of initial debulking procedures using laser, microsurgical, 
excision, or microdebrider to improve the airway and voice. Some children can require frequent removal, 
with intervals between surgery sometimes 3–4 weeks and occasionally even shorter.(Auborn, 2002) 
Interferon therapy and antivirals have been shown only to slow the progression of the papilloma growth, 
without demonstrating a cure. It has been suggested that tracheostomy placement may cause further 
spread of the papillomas into the trachea and bronchi; however it is equally likely that tracheotostomy 
placement is simply a marker of a more aggressive form of the disease. A small subset of patients with 
either JORRP or AORRP develop malignant degeneration to squamous cell carcinoma. The use of 
irradiation and other DNA damaging agents have been implicated as risk factors for malignant 
transformation as well.(Auborn, 2002)482
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Chemotherapeutics currently being studied as 
treatment options for RRP include indole-
3-carbinol, photodynamic therapy (PPT), inter-
feron, retinoid therapy, and HPV vaccination, used 
alone or in combination with surgical excision. 
None has been shown to cure the disease, 
but chemotherapy can prolong the duration of 
symptom free intervals. For each drug, the decision 
to treat must be weighed against the potential risk 
of malignant degeneration.
Case Report
W.E. a 75-year-old female with a long history of 
RRP in the larynx and trachea that required mul-
tiple excisions of the papillomas. The patient 
claimed to have had papillomas present in her 
larynx ever since the age of 2. Her ﬁ  rst docu-
mented surgery for RRP occurred at age 22. 
By 2000 (age 72) , she had undergone multiple 
surgeries for excision of the papillomas, estimated 
to be approximately 60–70. She had no known 
history of tobacco or alcohol use. In 2000, the 
papillomas became rapidly progressive with 
obstruction, and histopathologic examination 
revealed squamous cell carcinoma in situ. She 
underwent external beam radiation totaling 
6200 rads to the region encompassing the larynx, 
trachea and the upper mainstem bronchus. 
Initially, the tumors responded to the therapy, but 
regrew rapidly in 2001, requiring further excision. 
She was treated with 4 cycles of carboplatin 
(300 mg/m
2) and 5-FU (600 mg/m
2) given every 
3 weeks. Initially, W.E. responded to therapy, but 
the disease progressed again, requiring laser exci-
sion. Next, she was treated with methotrexate 
initially at 7.5 mg orally each week, decreasing 
to 5 mg orally weekly due to mucosal dryness, 
but, the papillomas continued to grow rapidly and 
a tracheotomy was required. A chest x-ray and 
CT scan revealed pulmonary nodules suspicious 
for metastases. The patient was lost to follow-up. 
In August of 2003, W.E. returned with symptoms 
of airway obstruction after a long hiatus 
with no therapy and received 2 cycles of 
continuous infusion 5-FU for ﬁ  ve days at a dose 
of 500 mg/m
2 per day. A repeat CT of chest and 
neck revealed mild interval progression of a few 
pulmonary nodules with no interval change in 
most of the lesions. She continued to be treated 
with frequent surgery and one month after treat-
ment with 5FU, biopsy in September, 2003, 
revealed invasive squamous cell carcinoma of the 
larynx. A CT-guided biopsy of her enlarging left 
lung base nodule revealed a high-grade squamous 
cell dysplasia. A laryngectomy was performed in 
October 2003 and chemotherapy was resumed 
with carboplatin and 5-FU. The chemotherapy 
was discontinued towards the end of February 2004 
after the patient experienced dizziness, tiredness, 
nausea, anorexia and eye pain. In February 2004, 
pegylated Interferon was started at a dose of 
50 mcg per week, which she tolerated very poorly. 
She was given Indole-3 carbamide (400 mg orally 
daily) and in March 2004, she had debridement 
of peristomal papillomas with injection of cido-
fovir, as well as bronchoscopy with Argon laser 
coagulation of papillomas in her distal airway. In 
July 2004 for stomal obstruction secondary to 
recurrent/worsening laryngeal tracheobronchial 
papillomatosis, an Argon laser coagulation 
(60minutes) was performed and the debulking of 
the tumor allowed mild relief of her symptoms. 
She developed a left neck mass, and a ﬁ  ne needle 
aspiration of the mass showed keratinizing squa-
mous cell carcinoma. She was not a candidate for 
further chemotherapy or radiation and was 
referred to hospice and expired in October 2004. 
Over the duration of her illness, medical input 
was obtained from Hematology-Oncology, ENT, 
Radiation Oncology and Pulmonary services. Her 
case was presented and further discussed at both 
ENT and pulmonary tumor boards and resulted 
in treatment plans derived from the consensus 
opinion.
Discussion
Surgery, radiation therapy, chemotherapy, Indole-
3-carbamide, Interferon (INF), and cidofovir were 
used in this case of JORRP, each of which was only 
transiently effective. Endoscopic removal remains 
the mainstay of treatment for respiratory papilloma-
tosis. Surgical techniques include laser, cold steel, 
and microdebrider. Repeated surgery can lead to 
scarring and stenosis. Radiation therapy was used 
as a treatment of desperation for this patient to pre-
vent impending obstruction after detection of squa-
mous cell carcinoma in situ, with an understanding 
that the radiation might promote future transforma-
tion to invasive malignancy. Radiation therapy has 
been implicated as causing malignant transforma-
tion and should usually be avoided unless malig-
nancy has been diagnosed. In this particular case, 483
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radiation therapy was beneficial in short term 
management of obstructive symptoms, although it 
may have accelerated progression to malignancy in 
the long term.(Auborn, 2002)
Indole-3-carbinol/diindolylmethan (I3C/DIM), 
commonly found in cruciferous vegetable, is the 
most benign adjuvant therapy for RRP.(Rosen and 
Bryson, 2004) The compounds I3C or DIM, a dimer 
of I3C, induces 2-hydroxylation of estradiol, 
forming 2-hydroxyoestrone, which is not estrogenic. 
HPV-6 and HPV-11 usually cause disease at trans-
formation zones such as the cervix or vocal cords, 
which are areas that tend to be hormonally sensitive. 
I3C/DIM also has antiproliferative effects in papil-
lomas and acts as a free radical scavenger.(Auborn, 
2002) Rosen and Bryson(Rosen and Bryson, 2004) 
found I3C to be a successful treatment option for 
RRP, with its efﬁ  cacy in children meriting fur-
ther study. After complete surgical removal of 
papillomas, 11 (33%) patients had remission of 
papilloma growth requiring no further debridement 
procedures while on I3C. Ten (30%) patients had a 
decreased papilloma growth. Twelve (36%) patients 
had no clinical response and no patients’ growth of 
papillomas increased. Rosen et al. concluded that 
I3C was safe and well tolerated.(Rosen et al. 1998) 
There are very few side affects with I3C/DIM treat-
ment. For unknown reasons, there are subsets of 
people that do not respond to I3C, and this could be 
related to differences in estrogen metabolism.(Rosen 
and Bryson, 2004)
Interferon-α therapy, is used as an adjuvant 
therapy and has been shown to slow the recurrence 
rate of RRP. The effectiveness of interferon appears 
to be dose related. INF-α induces cells to become 
resistant to various viruses, and decreases growth 
of certain cells. INF-α can cause ﬂ  u-like symptoms 
and problems with liver function tests. In 
1988, Kashkima found that interferon alpha-n1 
(Wellferon) was an effective adjuvant to surgery 
in treating RRP. In a 12-month randomized cross-
over study, 66 patients with clinically severe 
JORRP were evaluated. Statistically, signiﬁ  cant 
improvement occurred in patients receiving 
INF-α n-1.(Kashima et al. 1988) Healy demon-
strated in 1988 that interferon is neither curative 
nor of substantial value when used as an adjuvant 
agent in long-term management of RRP. In this 
study, 123 patients were randomly assigned to 
receive surgery plus INF, or surgery alone. Healy 
found that the initial effects of interferon 
were not maintained.(Healy et al. 1988) It has 
been shown that disease severity increases after 
cessation of INF-α. Because of the higher inci-
dence of side affects, INF-α tends to be used either 
after a patient has failed I3C therapy or along with 
I3C.(Auborn, 2002) In this case study, INF-α and 
I3C were used simultaneously.
Cidofovir is a nucleoside analogue that disrupts 
viral DNA synthesis and angiogenesis and pro-
motes apoptosis, and is particularly useful in RRP 
as it is a HPV-driven process. Cidofovir is normally 
used intralesionally for adjuvant treatment of 
RRP.(Snoeck, 1998) This decreases the chance of 
kidney damage that can occur with systemic 
cidofovir.(Auborn, 2002) In 1999, Pransky found 
that 4 out of 5 pediatric patients with severe RRP 
responded to intralesional cidofovir treatment. One 
patient was disease-free and 3 patients had a 
dramatic response at their 9-month follow-up visit.
7 
The use of Cidofovir was started late in the course 
of this patient’s disease process, and may perhaps 
have proved more beneﬁ  cial if started earlier in 
her disease course.
Understanding the molecular biology of RRP 
has advanced the adjuvant treatment options with 
concurrent surgical/laser debridement. In 1999, 
Bonagura found that patients with RRP had an 
elevated percentage of CD8 (+), CD28 (−) T-cells. 
They also found that many of the patients tested 
expressed an increase in the TH2-like cytokine 
mRNA in response to autologous papilloma tissue. 
Bonagura’s data suggested that patients with RRP 
do not form an adequate T-cell response to HPV. 
These alterations in the immune system could lead 
to different levels of disease severity.(Bonagura 
et al. 1999) In 1998, Rady discovered that only 
integrated forms of HPV-11 sequences were found 
in malignant tissue samples, and through molecu-
lar genetics demonstrated the allelic loss of INF-β 
gene and a mutation of p53 tumor suppressor gene 
in only malignant lesions. Rady also found that the 
p53 genetic mutation correlated with the integra-
tion of HPV-11 in malignant tissues.(Rady et al. 
1998) In 2004, DeVoti explored the cytokines 
expressed by peripheral blood mononuclear cells 
and T-cells from RRP patients that were exposed 
to puriﬁ  ed HPV early proteins E6 and E7. DeVoti’s 
results suggested that HPV-11 E6 alters the 
expression of IL-10 and INF-γ, towards increased 
expression of IL-10 versus INF-γ. They also found 
a hyporesponsiveness of TH1-like cytokines in 
response to E6 in patients with more severe disease. 
DeVoti suggested that it was this alteration 484
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in the immune response that contributed to 
the inability of a patient’s immune system to 
control RRP.(DeVoti, Steinberg, Rosenthal, 
Hatam, Vambutas, Abramson, Shikowitz, and 
Bonagura, 2004)
In 1998, McKaig et al. noted the overall preva-
lence of HPV in head and neck tumors was 34.5% 
(416 of 1205 tumors) with the frequency of HPV 
in benign and precancerous lesions ranging from 
18.5% to 35.9%. HPV positive tumors were also 
more often found to be the high risk types 16 and 18 
(40% and 11.9% respectively). HPV positive 
tumors were detected in the oral cavity more often 
(59%), then the pharynx (43%) or larynx (33%). 
McKaig et al. concluded that the high prevalence 
of HPV suggested a potential etiologic role in head 
and neck cancer.(McKaig RG et al. 1998) Li et al. 
in 2004 looked at cell marker expression and pres-
ence of HPV in ﬁ  fty cases of SCC of the tonsil. 
HPV, mostly type 16, was identiﬁ  ed in 42% of 
cases with a statistical association between reduced 
expression of pRb and cyclinD1, overexpression 
of p16, and a younger patient age. Li et al. 
concluded that HPV-positive SCC of the tonsil has 
a distinct molecular pathway with from HPV-
negative tumors.(Li W. et al. 2004) When looking 
at younger versus older patients with SCC of the 
head and neck, Sisk found the incidence of HPV 
to not be significantly different between the 
groups studied. Interestingly, Sisk et al. noted 
some survival advantage in patients bearing 
HPV-positive tumors relative to patients with 
HPV-negative tumors.(Sisk et al. 2000)
In this case report, it became evident that 
JORRP, with progression to squamous cell carci-
noma, initially responded to multiple agents includ-
ing chemotherapy regimens of carboplatin and 
5-FU. It also became evident that JORRP then 
developed resistance to these agents, and progres-
sion of disease occurred. Photodynamic therapy 
(PDT), additional antiviral medications, HPV 
vaccination, retinoid treatment, and velcade are all 
novel agents developed to further control the 
progression of disease in RRP.
PDT uses a photosensitizing dye that the 
neoplastic cells selectively take up. These 
tissue regions are then exposed to a certain wave-
length via an argon laser. This creates a singlet 
oxygen reaction resulting in an anti-angiogenic 
effect.(Auborn, 2002) In 1998, Shikowitz using 
Dihematoporphyrinether (DHE) PDT demon-
strated in a randomized prospective trial that 
patients receiving either 3.25 mg/kg or 4.25 mg/kg 
dose showed notable improvement over the ﬁ  rst 
year. Patients receiving the dose 4.25 mg/kg dem-
onstrated a signiﬁ  cantly larger decrease in papil-
loma growth rate. The improvement in a subset of 
people was maintained at the 3-year follow-
up.(Shikowitz et al. 1998) DHE can leave patients 
sensitive to light for approximately 2 months. 
In 2005, Schikowitz used a newer PDT agent, 
meso-tetra hydroxyphenyl chlorine (mTHC), or 
Foscan, and it reduced the severity of laryngeal 
papillomas, but failed to maintain remission. Five 
of the 15 patients were in remission 12–15 months 
after treatment, but had disease reoccurrence after 
3–5 years. Out of the 23 patients (ages 4–60 years) 
that initially began this study, only 15 people were 
available for follow-up. Shikowitz concluded that 
mTHC was not an optimal treatment.(Shikowitz 
et al. 2005)
Other antivirals such as acyclovir and ribavirin 
offer promise as additional adjuvant therapies for 
RRP resistant to other modalities. Acyclovir, a 
purine analogue, is preferentially activated by 
thymidine kinases encoded by herpes viruses and 
is then incorporated into viral DNA causing strand 
breakage. Although the papillomavirus does not 
preferentially activate thymidine kinase, there have 
been clinical responses to acyclovir in patients with 
RRP. The current hypothesis is that a co-infection 
with herpes virus may exist. Ribavirin, a guanosine 
analogue, inhibits GTP synthesis and prevents 
RNA synthesis. There is not much literature about 
the efﬁ  cacy of using ribavirin in patients with RRP. 
However, a small randomized study in the United 
States demonstrated an increase in the intervals 
between surgeries.(Auborn, 2002)
The use of various vaccinations is aimed at both 
prevention and treatment of RRP. Therapeutic vac-
cinations can target a non-structural viral protein 
such as E6 or E7 for speciﬁ  c targeting HPV induced 
papillomas or enhance a non-speciﬁ  c immune 
system response locally by the presentation of 
a foreign antigen (e.g. mumps vaccine). There are 
some therapeutic and preventive vaccines that are 
being studied, such as TA-GW, which has a fusion 
protein of E7 and L2.(Auborn, 2002) In 2005, 
Pashley(Pashley, 2002) discovered that the mumps 
vaccination, in combination with serial laser 
debridement, was able to induce remission in chil-
dren with RRP. After laser excision of the papil-
loma, the mumps vaccine was locally administered 
and in the pilot study Pashley found that remission 485
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occurred in 9 of 11 children (82%) with RRP 
after 1–10 vaccine injections, with a follow up of 
5–10 years. In the other series, Pashley found that 
remission was induced in 29 of 38 patients (76%) 
by 4–26 injections, with a follow-up of 2–5 years. 
This subsequent series was composed of 18 chil-
dren and 20 adults.(Pashley, 2002) Preventive 
vaccinations used against speciﬁ  c strains of HPV 
use recombinant viral L1 capsid proteins. The FDA 
has approved 1 HPV vaccine, Gardasil, which 
protects against infection from HPV 6, 11, 16 and 
18. This vaccine should prevent infection with the 
2 HPV subtypes (6, 11) most commonly associated 
with RRP, and theoretically enable primary preven-
tion of the disease.(Harper et al. 2006)
Retinoids, both cis-retinoic acid or isotretinoin 
(accutane), have been used as adjuvant therapy in 
a small number of patients with RRP. Retinoids 
may inhibit growth of papillomas by inhibiting cell 
proliferation and angiogenesis. Results using 
cis-retinoic acid for RRP have demonstrated some 
success in decreasing disease progression. Toxicity 
of retinoids suspended 1 study which concluded 
the therapy to be ineffective.(Auborn, 2002)
Bortezomib (formerly PS-341), or Velcade, 
was approved by the FDA for treatment of 
multiple myeloma. Velcade inhibits the proteo-
lytic activity of the proteosome complex in mam-
malian cells.(Kane et al. 2003) With Rady 
demonstrating a mutation of p53 suppressor gene 
found only malignant lesions and that a p53 
genetic mutation correlated with the integration 
of HPV-11 in malignant tissues, Velcade may be 
a possible agent to use as adjuvant therapy in 
RRP.(Rady, Schnadig, Weiss, Hughes, and Tyring, 
1998) HPV E6 binds to p53 and targets it for 
ubiquitin conjugation followed by proteasome 
degradation. Because of its potential to block p53 
degradation intracellularly, Velacade is the ﬁ  rst 
anti-cancer therapy to target the proteasome for 
inhibition and may be a valuable tool to treat later 
stage adult RRP. When tested in patients with 
multiple myeloma, the common adverse affects 
were asthenic conditions, nausea, vomiting, diar-
rhea, thrombocytopenia, and a peripheral 
neuropathy that was commonly painful.(Kane, 
Bross, Farrell, and Pazdur, 2003)
In this case study, we found that longstanding 
JORRP, ultimately progressing to invasive squa-
mous cell carcinoma, initially responded to a 
chemotherapy regimen of 4 cycles of carboplatin 
(300 mg/m
2) and 5-FU (600 mg/m
2). We also found 
that the use of methotrexate did not halt the 
progression of the papillomas. Additionally, the 
use of carboplatin and 5-FU initially decreased 
the growth of the papillomas after squamous cell 
carcinoma in situ developed. However, the papil-
lomas ultimately became resistant to therapy and 
the disease progressed to invasive carcinoma. 
Nonetheless, this case report offers the option of 
using a chemotherapy regimen for longstanding 
JORRP with progression to squamous cell carci-
noma. With advancements in immune treatments, 
antivirals, and other novel agents such as PDT, 
further treatment options for longstanding JORRP 
do exist and HPV vaccination may make primary 
prevention of this disease possible.
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